Testing
Lp(a) stays stable at the extremes, but women, statin users and those with ASCVD or high LDL-C are more likely to see borderline levels shift, 11,669-patient Mayo Clinic study finds (Eur J Prev Cardiol 2025)
Original title: Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population
This study examined 11,669 adults from a large academic health system with baseline and follow-up Lp(a) measurements taken between 1997 and 2024, at least a year apart (median 4.5 years), to characterise intra-individual Lp(a) variability across normal (below 30 mg/dL), borderline (30-50) and high (50 mg/dL or above) categories. Median Lp(a) was 16 mg/dL at baseline and 15 mg/dL at follow-up; 96.4% of those with normal Lp(a) and 89.9% of those with high Lp(a) stayed in their category, while 51.2% of those with borderline Lp(a) changed category, and 24.9% of the cohort had an intra-individual change of 10 mg/dL or more. Female sex, history of ASCVD, statin therapy, and LDL-C of 100 mg/dL or above were each significantly associated with higher odds of such a change (all P less than 0.003). The authors conclude Lp(a) is generally stable, but patients with borderline levels, especially women, those with ASCVD, high LDL-C or on statins, may warrant a repeat measurement.
Original abstract
Aims: Lipoprotein(a) (Lp(a)) levels are known to be mainly genetically determined. However, only scarce data are available on the intra-individual variability of Lp(a) levels across time.
Methods And Results: We included adult patients (≥18 years old) who had baseline and follow-up Lp(a) measurements (between 1997 and 2024) with a minimum of 1 year apart. Patients were categorized into three groups as follows: normal (<30 mg/dL), borderline (30 to 50 mg/dL), and high Lp(a) (≥50 mg/dL). Multivariable logistic regression was conducted to assess the predictors of the intra-individual changes in Lp(a) ≥ 10 mg/dL. A total of 11 669 individuals (median age: 54 years, 60% males) were included in our analysis, with median time between measurements of 4.5 years [interquartile range (IQR): 2.2, 10.6]. The median Lp(a) was 16 mg/dL (IQR: 7, 52) at baseline, compared with 15 mg/dL (IQR: 7, 52) at follow-up. At follow-up, 96.4% of individuals with normal Lp(a) and 89.9% with high Lp(a) remained in their categories, while 51.2% with borderline Lp(a) changed their category. Of the included population, 24.9% had an intra-individual Lp(a) change ≥ 10 mg/dL. Female sex (P < 0.001), history of ASCVD (P = 0.003), statin therapy (P = 0.003), and elevated LDL cholesterol (LDL-C) levels ≥ 100 mg/dL (P < 0.001) were significantly associated with higher odds of intra-individual Lp(a) changes ≥ 10 mg/dL.
Conclusion: Lipoprotein(a) levels were generally stable over time; however, patients with borderline levels may require more than one Lp(a) measurement, especially if they are females, have a history of ASCVD, have elevated LDL-C levels, or are on statin therapy.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.